InsuletPODD
About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Employees: 3,900
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
133% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 52
13% more capital invested
Capital invested by funds: $16.2B [Q3] → $18.4B (+$2.19B) [Q4]
9% more funds holding
Funds holding: 611 [Q3] → 668 (+57) [Q4]
1.04% more ownership
Funds ownership: 99.37% [Q3] → 100.41% (+1.04%) [Q4]
10% more repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 222
31% less call options, than puts
Call options by funds: $123M | Put options by funds: $177M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Barclays Matt Miksic 48% 1-year accuracy 20 / 42 met price target | 5%upside $266 | Equal-Weight Maintained | 30 Apr 2025 |
RBC Capital Shagun Singh 49% 1-year accuracy 33 / 68 met price target | 35%upside $340 | Outperform Initiated | 6 Mar 2025 |
Citigroup Joanne Wuensch 45% 1-year accuracy 18 / 40 met price target | 41%upside $355 | Buy Maintained | 21 Feb 2025 |
Raymond James Jayson Bedford 44% 1-year accuracy 12 / 27 met price target | 30%upside $328 | Outperform Reiterated | 21 Feb 2025 |
Stifel Mathew Blackman 35% 1-year accuracy 6 / 17 met price target | 16%upside $293 | Hold Maintained | 21 Feb 2025 |
Financial journalist opinion
Based on 8 articles about PODD published over the past 30 days
